Related Experiment Video
Updated: Dec 22, 2025
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
[Development of a new assessment for cardio-oncology and its international trend]
Ayano Satsuka1, Yasunari Kanda1
1Division of Pharmacology, National Institute of Health Sciences (NIHS).
Abstract:
Cardiac safety assessments play a key role in drug development. New non-clinical cardiac safety risk assessments, such as the use of iPSC-derived cardiomyocytes, have been validated by several consortiums both in Japan and abroad. The emerging multidisciplinary field of cardio-oncology has been recognized more important. The success of new cancer therapies has improved life expectancy of cancer patients, hence more attention has been paid to cardiotoxicities associated with existing and new anti-cancer therapies, such as cardiomyocyte injury and heart failure, vascular injury and hypertension or thrombosis, which accelerated coronary artery disease. In addition to the well-studied proarrhythmia risk, some cardiotoxicities, such as contractility impairment, are expected to be evaluated by iPSC-derived cardiomyocytes. Here we developed a novel imaging-based in vitro contractility assay using iPSC-derived cardiomyocytes. In the review, we would like to discuss the current status and future perspectives in the assessment of cardiac contractile function by anti-cancer agents.
Insights
This study introduces a new imaging assay using induced pluripotent stem cell-derived cardiomyocytes to assess drug-induced cardiac contractility impairment. This method aids in evaluating cardiotoxicity risks from anti-cancer therapies.
Area of Science:
- Drug development
- Cardio-oncology
- Cardiovascular research
Background:
- Cardiac safety is crucial in drug development, with increasing focus on cardio-oncology due to improved cancer patient survival.
- Anti-cancer therapies can cause cardiotoxicities like heart failure and accelerated coronary artery disease.
- Assessing contractility impairment is vital, alongside proarrhythmia risks.
Purpose of the Study:
- To develop and discuss a novel imaging-based in vitro contractility assay.
- To evaluate the cardiac contractile function affected by anti-cancer agents.
- To review the current status and future perspectives in assessing anti-cancer drug cardiotoxicity.
Main Methods:
- Utilized induced pluripotent stem cell (iPSC)-derived cardiomyocytes.
- Developed a novel imaging-based in vitro contractility assay.
- Discussed current and future perspectives in cardiac safety assessment.
Main Results:
- Successfully developed a novel imaging-based assay for in vitro contractility.
- The assay is designed to evaluate cardiotoxicity, specifically contractility impairment.
- The study sets the stage for further research in this area.
Conclusions:
- The developed iPSC-derived cardiomyocyte assay offers a new approach for assessing drug-induced cardiac contractility.
- This assay is valuable for evaluating cardiotoxicity of anti-cancer agents.
- Further research and validation are needed to fully integrate this method into drug development.
More Related Videos
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
Related Concept Videos
01:25Assessment of the Cardiovascular System IV: Auscultation
Normal Heart Sounds
S1 (First Heart Sound)-
S1 is made by the closure of the mitral and tricuspid valves (atrioventricular valves), marking the beginning of systole.
S2 (Second Heart Sound)-
S2 is made by the closure of the aortic and pulmonic valves (semilunar valves), marking the end of the systole.
01:23Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
01:29Nursing Assessment
The nurse collects all aspects of the patient's health in the initial assessment, establishing priorities for ongoing focused assessments...
01:27Assessment of the Cardiovascular System III: Palpation
Jugular Venous Pressure (JVP) Measurement
Position the patient at a thirty- to forty-five-degree angle or in a semi-fowler's position. Look for the highest point of pulsation in the internal jugular vein and measure the vertical distance to the angle of Loius or sternal angle. A normal JVP is 3-4 cm above...
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:17Assessment of apical pulse
Assessing the apical pulse is a critical nursing procedure, particularly indicated for: